Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) shares traded up 24.1% during mid-day trading on Tuesday . The stock traded as high as C$1.72 and last traded at C$1.70. 892,106 shares traded hands during trading, an increase of 556% from the average session volume of 135,968 shares. The stock had previously closed at C$1.37.
Wall Street Analysts Forecast Growth
Separately, Jones Trading lowered shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.
Read Our Latest Analysis on ONC
Oncolytics Biotech Stock Up 24.1%
The business has a 50-day moving average price of C$0.76 and a two-hundred day moving average price of C$0.93. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The firm has a market cap of C$131.03 million, a PE ratio of -4.74 and a beta of 1.35.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
